Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia

被引:85
作者
Brisco, MJ
Hughes, E
Neoh, SH
Sykes, PJ
Bradstock, K
Enno, A
Szer, J
McCaul, K
Morley, AA
机构
[1] FLINDERS UNIV S AUSTRALIA, MED CTR, DEPT HEMATOL, BEDFORD PK, SA 5042, AUSTRALIA
[2] WESTMEAD HOSP, DEPT HEMATOL, WESTMEAD, NSW, AUSTRALIA
[3] NEWCASTLE MATER MISERICORDIAE HOSP, DEPT HEMATOL, NEWCASTLE, NSW, AUSTRALIA
[4] ROYAL MELBOURNE HOSP, BONE MARROW TRANSPLANT SERV, MELBOURNE, VIC, AUSTRALIA
[5] S AUSTRALIAN HLTH COMMISS, ADELAIDE, SA, AUSTRALIA
关键词
D O I
10.1182/blood.V87.12.5251.bloodjournal87125251
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In children with acute lymphoblastic leukemia (ALL), the level of minimal residual disease (MRD) at the end of induction strongly predicts outcome, presumably because it measures both drug sensitivity and the number of leukemic cells requiring elimination, Children with high levels (>10(-3) leukemic cells per marrow cell) nearly always relapse, whereas those with low levels (<2 x 10(-5)) seldom do, However, the importance of MRD in adult ALL is unclear, We studied 27 patients aged 14 to 74 who were treated with a standard protocol and who attained morphological remission. MRD in the marrow at first remission was quantified by using the polymerase chain reaction (PCR), with the rearranged immunoglobulin heavy chain gene as a molecular marker. Levels of MRD varied from 3 x 10(-1) to <7 x 10(-7). The probability of long-term relapse-free survival was significantly related to the level of MRD and only one of nine patients with MRD >10(-3) did not relapse. For patients who did relapse, there was an inverse relationship between MRD level and the length of remission. Overall, MRD in adults in whom a translocation had not been identified was significantly higher than in comparably-treated children, suggesting that ALL in adults is more drug-resistant than in children. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:5251 / 5256
页数:6
相关论文
共 35 条
  • [21] DETECTION OF MINIMAL RESIDUAL DISEASE IN T-CELL ACUTE LYMPHOBLASTIC-LEUKEMIA USING POLYMERASE CHAIN-REACTION PREDICTS IMPENDING RELAPSE
    NEALE, GAM
    MENARGUEZ, J
    KITCHINGMAN, GR
    FITZGERALD, TJ
    KOEHLER, M
    MIRRO, J
    GOORHA, RM
    [J]. BLOOD, 1991, 78 (03) : 739 - 747
  • [22] NIZET Y, 1993, BLOOD, V82, P1618
  • [23] OUSPENSKAIA MV, 1995, LEUKEMIA, V9, P321
  • [24] RELATION OF CELLULAR-DRUG RESISTANCE TO LONG-TERM CLINICAL OUTCOME IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    PIETERS, R
    HUISMANS, DR
    LOONEN, AH
    HAHLEN, K
    VANDERDOESVANDENBERG, A
    VANWERING, ER
    VEERMAN, AJP
    [J]. LANCET, 1991, 338 (8764) : 399 - 403
  • [25] ADVANCEMENT OF MULTIPLE-MYELOMA FROM DIAGNOSIS THROUGH PLATEAU-PHASE TO PROGRESSION DOES NOT INVOLVE A NEW B-CELL CLONE - EVIDENCE FROM THE IG HEAVY-CHAIN GENE
    RALPH, QM
    BRISCO, MJ
    JOSHUA, DE
    BROWN, R
    GIBSON, J
    MORLEY, AA
    [J]. BLOOD, 1993, 82 (01) : 202 - 206
  • [26] SALO A, 1993, LEUKEMIA, V7, P1459
  • [27] Prognostic value of early response to chemotherapy assessed by the day 15 bone marrow aspiration in adult acute lymphoblastic leukemia: A prospective analysis of 437 cases and its application for designing induction chemotherapy trials
    Sebban, C
    Browman, GP
    Lepage, E
    Fiere, D
    [J]. LEUKEMIA RESEARCH, 1995, 19 (11) : 861 - 868
  • [28] SYKES PJ, 1992, BIOTECHNIQUES, V13, P444
  • [29] TYCKO B, 1989, CANCER CEL, V7, P47
  • [30] VEELKEN H, 1991, BLOOD, V78, P1318